Markets

Corona Remedies Shares Debut At 38% Premium Over IPO Price

December 15, 2025

Corona Remedies Ltd. made a strong debut on the stock market on December 15, listing at ₹1,461 on the NSE and ₹1,452 on the BSE, representing a premium of 37.57% and 36.72% over its IPO price, respectively. The IPO, which closed on December 10, was highly successful, being oversubscribed 144.54 times, with significant demand from qualified institutional buyers and retail investors.

Corona Remedies Shares Debut At 38% Premium Over IPO Price

Credit: Feedburner

Key Highlights

Corona Remedies shares debuted at ₹1,461 on NSE and ₹1,452 on BSE.
The IPO was priced between ₹1,008 and ₹1,062 and raised ₹655.37 crore.
The IPO was oversubscribed 144.54 times, with QIBs subscribing 278.52 times.
The grey market premium before listing was ₹342.50 per share.
The allotment for the IPO was finalized on December 11.

Markets

Sources

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.

Corona Remedies Shares Debut At 38% Premium Over IPO Price

Key Highlights

Sources

Related Stories

S&P 500 has gained 16% in Trump’s first year back in office. How that compares with other presidents.

Badenoch at odds with Jenrick over 'broken' Britain

Odisha police start crackdown on organised cattle traders at 46 locations